Prevalence of fosfomycin resistance and mutations in murA, glpT, and uhpT in methicillin-resistant Staphylococcus aureus strains isolated from blood and cerebrospinal fluid samples

Frontiers in Microbiology

Volumn 6, Issue JAN, 2016, Pages

  Fu, Zhuyingjie ^a,b   Ma, Ying ^a,b   Chen, Chunhui ^a,b   Guo, Yan ^a,b   Hu, Fupin ^a,b   Liu, Yang ^a   Xu, Xiaogang ^a   Wang, Minggui ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Fosfomycin; MRSA; Mutations; Resistance; Staphylococcus aureus

Indexed keywords

FOSFOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; FOSB GENE; FOSC GENE; GENE MUTATION; GLPT GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MURA GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UHPT GENE;

EID: 84958025978     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.01544     Document Type: Article

References (18)

1. Aanensen, D. M., and Spratt, B. G. (2005). The multilocus sequence typing network, mlst.net. Nucleic Acids Res. 33, W728-W733. doi: 10.1093/nar/gki415.
2. Chen, C., Xu, X., Qu, T., Yu, Y., Ying, C., Liu, Q., et al. (2014). Prevalence of the fosfomycin-resistance determinant, fosB3, in Enterococcus faecium clinical isolates from China. J. Med. Microbiol. 63, 1484-1489. doi: 10.1099/jmm.0.077701-0.
3. Clinical and Laboratory Standards Institute [CLSI]. (2014). Performance Standards for Antimicrobial Susceptibility Testing: Twenty Fourth Informational Supplement, M100-S24, Vol. 34. Wayne, PA: Clinical and Laboratory Standards Institute.
4. DeLeo, F. R., and Chambers, H. F. (2009). Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J. Clin. Invest. 119, 2464-2474. doi: 10.1172/JCI38226.
5. Del Río, A., Gasch, O., Moreno, A., Peña, C., Cuquet, J., Soy, D., et al. (2014). Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus, A multicenter clinical trial. Clin. Infect. Dis. 59, 1105-1112. doi: 10.1093/cid/ciu580.
6. Enright, M. C., and Spratt, B. G. (1999). Multilocus sequence typing. Trends Microbiol. 7, 482-487. doi: 10.1016/S0966-842X(99)01609-1.
7. Etienne, J., Gerbaud, G., Fleurette, J., and Courvalin, P. (1991). Characterization of staphylococcal plasmids hybridizing with the fosfomycin resistance gene fosB. FEMS Microbiol. Lett. 68, 119-122. doi: 10.1111/j.1574-6968.1991.tb04580.x.
8. European Committee on Antimicrobial Susceptibility Testing [EUCAST] (2012). Available at: http://www.eucast.org.
9. Falagas, M., Maraki, S., Karageorgopoulos, D. E., Kastoris, A. C., Kapaskelis, A., and Samonis, G. (2010). Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int. J. Antimicrob. Agents 35, 497-499. doi: 10.1016/j.ijantimicag.2010.01.010.
10. Falagas, M., Roussos, N., Gkegkes, I., Rafailidis, P. I., and Karageorgopoulos, D. E. (2009). Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance, a review of microbiological, animal and clinical studies. Exp. Opin. Investig. Drugs 8, 921-944. doi: 10.1517/13543780902967624.
11. Fillgrove, K., Pakhomova, S., Schaab, M. R., Newcomer, M. E., and Armstrong, R. N. (2007). Structure and mechanism of the genomically encoded fosfomycin resistance protein, fosx, from Listeria monocytogenes. Biochemistry 46, 8110-8120.
12. García, P., Arca, P., and Evaristo, S. J. (1995). Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate. Antimicrob. Agents Chemother. 39, 1569-1573. doi: 10.1128/AAC.39.7.1569.
13. Guo, Y., Zhu, D., Hu, F., Wang, F., Yu, Y., Yang, Q., et al. (2013). CHINET 2010 surveillance and analysis of antibiotic resistance in Staphylococcus spp. in China. Chin. J. Infect. Chemother. 13, 86-92.
14. Jiang, S., Gilpin, M. E., Attia, M., Ting, Y. L., and Berti, P. J. (2011). Lyme disease enolpyruvyl-UDP-GlcNAc synthase: fosfomycin-resistant MurA from Borrelia burgdorferi, a fosfomycin-sensitive mutant, and the catalytic role of the active site Asp. Biochemistry 12, 2205-2212. doi: 10.1021/bi1017842.
15. Lee, S. Y., Park, Y. J., Yu, J. K., Jung, S., Kim, Y., Jeong, S. H., et al. (2012). Prevalence of acquired fosfomycin resistance among extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J. Antimicrob. Chemother. 67, 2843-2847. doi: 10.1093/jac/dks319.
16. Michalopoulos, A. S., Livaditis, I. G., and Gougoutas, V. (2011). The revival of fosfomycin. Int. J. Infect. Dis. 15, e732-e739. doi: 10.1016/j.ijid.2011.07.007.
17. Sultan, A., Rizvi, M., Khan, F., Sami, H., Shukla, I., and Khan, H. M. (2015). Increasing antimicrobial resistance among uropathogens, Is fosfomycin the answer? Urol. Annal. 7, 26-30. doi: 10.4103/0974-7796.148585.
18. Takahata, S., Ida, T., Hiraishi, T., and Sakakibara, S. (2010). Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int. J. Antimicrob. Agents 2010, 333-337. doi: 10.1016/j.ijantimicag.2009.11.011.